Revisiting the Molecular and Cell Biology of the Hepatitis B Virus Towards Elimination | Fabien Zoulim, MD, PhD

HEP DART 2017

Update on Merck’s HCV Program | Mike Robertson

HEP DART 2017

Pan-genotypic direct-acting antiviral agents: Opportunity to achieve HCV elimination | Tarik Asselah

HEP DART 2017

DAA Controversies: Do they Cause HBV Reactivation and/or HCC? | Jordan Feld, MD, MPH

HEP DART 2017

Management of HCV in Decompensated liver disease | Michael Manns

HEP DART 2017

Clinical Challenges in HCV infection | Mark Sulkowski, MD

HEP DART 2017

SB 9200: A novel RIG-I agonist for chronic hepatitis B | Stephen Locarnini, BSc(Hons), PhD, MBBS, FRC(Path)

HEP DART 2017

Development of Immune Competent Small Animal Models for HBV | Helene Strick-Marchand

HEP DART 2017

Core Antibody: anti-HBc What is the Core of the Story? | Robert Gish, MD

HEP DART 2017

Endpoints and New Targets for Curing Hepatitis B | Stephen Locarnini, BSc(Hons), PhD, MBBS, FRC(Path)

HEP DART 2017

Is Host Genome Integrated HBV Relevant? - The Con Perspective | Stephen Locarnini, BSc(Hons), PhD, MBBS, FRC(Path)

HEP DART 2017

Personalized Approaches to HBV Cure | Marion Peters, MD

HEP DART 2017

Immunology of HBV | Adam Gehring, PhD

HEP DART 2017

Short Duration DAA HCV Therapy: How Short Can We Go? | Shyam Kottilil, MD, PhD

HEP DART 2017

DAA Therapy and Reinfection Among People who Inject Drugs: Forming a Foundation for HCV Elimination | Jason Grebely

HEP DART 2017

Liver Disease in Chinese-perspective from a Hepatologist | George Lau, MBBS, MRCP, FHKCP, FHKAM, MD, FRCP

HEP DART 2017

Access to HIV, HBV, and HCV Antiviral Agents Globally | John Martin, PhD

HEP DART 2017

Global Strategies to Eliminate Hepatitis B (ICE-HBV) | Peter Revill

HEP DART 2017

Consensus AASLD-EASL HBV Treatment Endpoint and HBV Cure Definition | Anna S. Lok, MD, DSc

HEP DART 2017

The French and European Approach Towards Hepatitis Elimination | Tarik Asselah, MD, PhD

HEP DART 2017

Elimination of HCV: The DC Story | Henry Masur, MD

HEP DART 2017

Strategy for the Elimination of Hepatitis B and C (Academy of Medicine Report) | Andrew Aronsohn, MD

HEP DART 2017

Eliminating Hepatitis C by 2030 - Enhancing prevention care and treatment among people who inject drugs | Margaret Hellard, AM, MBBS, FRACP, FAFPHM, PhD

HEP DART 2017

What challenges remain in viral hepatitis | Jürgen Rockstroh, MD

International Workshop on HIV & Hepatitis Co-infection 2017